Updated on 21 July 2014
20th International AIDS Conference (AIDS 2014) Photo Courtesy: International AIDS Society
Singapore: Investment in HIV prevention research has declined posing a challenge to the pipeline of HIV prevention products in various stages of development and implementation of an effective HIV treatment.
According to the tenth annual report by Working Group, a collaboration between AIDS Vaccine Advocacy Coalition (AVAC), UNAIDS, and the International AIDS Vaccine Initiative (IAVI), HIV Prevention Research and Development Investment in 2013, United States and European Union combined has slashed HIV research budget by $50 million, a drop by four percent, to the total value $1.26 billion in 2013.
The report was released ahead of the 20th International AIDS Conference (AIDS 2014) in Melbourne, held from July 20th-25th.
US is the single largest funder of prevention research, accounting for more than 70 percent of total investment over the past five years and the contribution has decreased by $44 million to the value of $881 million in 2013. Funding from European government donors, including 12 countries and the European Commission, was also reduced as priorities for international development in some countries have continued to shift.
"Research and development has produced a valuable range of medicines, diagnostics and devices to prevent and treat HIV which have to be made more widely available. However, funding is declining at a time when services need to be expanded and better treatments and additional HIV prevention options are needed," said Luiz Loures, deputy executive director, UNAIDS. "Now is not the time to pull back from science, but rather to push forward towards ending the AIDS epidemic."